ContraFect (CFRX) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPS

ContraFect (NASDAQ:CFRX) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.17, MarketWatch Earnings reports.

Shares of NASDAQ CFRX opened at $0.40 on Friday. The firm has a market cap of $32.16 million, a price-to-earnings ratio of -1.08 and a beta of -0.49. ContraFect has a 12-month low of $0.35 and a 12-month high of $2.93.

An institutional investor recently raised its position in ContraFect stock. Geode Capital Management LLC raised its stake in shares of ContraFect Corp (NASDAQ:CFRX) by 8.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 377,908 shares of the biotechnology company’s stock after acquiring an additional 29,009 shares during the quarter. Geode Capital Management LLC owned approximately 0.48% of ContraFect worth $578,000 at the end of the most recent reporting period. 55.57% of the stock is currently owned by institutional investors.

Separately, ValuEngine cut ContraFect from a “buy” rating to a “hold” rating in a research report on Thursday, December 6th.

COPYRIGHT VIOLATION WARNING: “ContraFect (CFRX) Announces Quarterly Earnings Results, Beats Estimates By $0.17 EPS” was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2019/03/15/contrafect-cfrx-announces-quarterly-earnings-results-beats-estimates-by-0-17-eps.html.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Read More: QQQ ETF

Earnings History for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.